During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
|Videos|May 21, 2020
A 68-Year-Old Man With Metastatic EGFR+ NSCLC
Author(s)John Heymach, MD, PhD
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
Advertisement
Case:A 68-Year-Old Man With Metastatic EGFR+ NSCLC
Initial presentation
- A 68-year-old man presented with recent onset shortness of breath and unintentional weight loss; he denies nausea, vomiting or headaches
- PMH: Hyperlipidemia controlled on a statin; former smoker, quit 10 years ago with a 30 pack-year history
- PE: Decreased breath sounds in left lower lung field on auscultation
Clinical workup
- Labs: WNL
- PFT: FEV1/FVC 55%; DLCO 65%
- Chest X-ray showed a left lower lobe soft tissue mass
- Chest/abdominal/pelvic CT showed a 3.3-cm solid pulmonary mass involving the left main bronchus and ipsilateral subcarinal lymph nodes, and adrenal metastases
- CT-guided core needle biopsy lung lesion and lymph nodes revealed grade 2 lung adenocarcinoma
- Contrast‐enhanced MRI of the brain was negative
- Molecular testing: EGFR exon 19 deletion, ALK-, ROS1-, BRAF-, PD-L1 TPS 20%
- Stage IVA – T2N2M1a; ECOG PS 1
Treatment
- Patient was started on erlotinib 150 mg PO qDay + ramucirumab 10 mg/kg IV q2weeks
- Imaging at 3-month showed partial response with decrease size of lung and adrenal lesions
- Imaging at 6-, 12- and 18-month follow-up showed stable disease
Advertisement
Related to this article
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5